Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Chris Calabrese , Linkedin , Nasdaq , Fulcrum Therapeutics Inc , Lifesci Advisors , Stock Incentive Plan , Nasdaq Listing Rule , Sci Advisors , Region ,